| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Pirogova Olga, SVP and CHRO
Received 10,339 shares as a grant or award · Received 13,412 shares as a grant or award · Gave up 7,081 shares to cover exercise price or tax ($311K) |
| 16 Nov 2026 |
Form 4: Lin Lawrence Y., EVP, CFO and Treasurer
Received 23,262 shares as a grant or award · Gave up 4,413 shares to cover exercise price or tax ($194K) |
| 16 Nov 2026 | Form 4 |
| 16 Nov 2026 | Form 4 |
| 16 Nov 2026 | Form 4 |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-thro... |
| 23 Oct 2026 |
Form 4: Madaus Martin D, Interim CEO
Gave up 1,294 shares to cover exercise price or tax ($46.6K) |
| 07 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Material Impairments
On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment. The Plan is intended primarily to co... |
| 23 Sep 2026 |
Form 4: Madaus Martin D, Interim CEO
Gave up 1,456 shares to cover exercise price or tax ($49.9K) |
| 17 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously disclosed in the Company’s Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Dr. Martin D. Madaus as the Company’s Interim President and Chie... |
| 16 Sep 2026 |
Form 4: Madaus Martin D, Interim CEO
Received 36,653 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Martin William E. Iii, President Multiomics
Received 15,272 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Pirogova Olga, SVP and CHRO
Received 15,272 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Lin Lawrence Y., EVP, CFO and Treasurer
Received 30,544 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Starr Ephraim, SVP, Gen Counsel & Secretary
Received 15,272 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Bello Erik J., VP Chief Accounting Officer
Received 4,586 shares as a grant or award |
| 09 Sep 2026 |
Form 3: Bello Erik J., VP Chief Accounting Officer
No securities owned |
| 04 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., September 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior... |
| 24 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
AZENTA ANNOUNCES LEADERSHIP TRANSITION Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., August 24, 2026 – Azenta, Inc. (N... |
Loading...